Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress

Download PDF Copy

Editorial Checklist

Reviewed

Infinity Pharmaceuticals, Inc.Sep 23 2010

Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35^th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.

The poster, entitled "A Phase 1 study of IPI-926, an inhibitor of the Hedgehog pathway, in patients with advanced or metastatic solid tumors," will be presented by Antonio Jimeno, M.D., Ph.D., Associate Professor, University of Colorado School of Medicine, during the Developmental Therapeutics session, which will take place from 12:30 – 3:30 p.m. CEST (6:30 – 9:30 a.m. EDT) on Sunday, October 10, 2010 in Yellow Hall 1.

A copy of the poster will be available on Infinity's website, www.infi.com, following its presentation.

Source:

Infinity Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: Cancer, Emerging Disease, Gemcitabine, Gemzar, Hedgehog Signaling, Medicine, Oncology, Pancreatic Cancer, Pharmaceuticals, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Aging reduces cancer risk by limiting cell regeneration

Aging reduces cancer risk by limiting cell regeneration

Annona squamosa extracts show promise in treating pain and arthritis

Annona squamosa extracts show promise in treating pain and arthritis

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

New study reveals complex attitudes toward psychedelic therapy

New study reveals complex attitudes toward psychedelic therapy

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Obesity crisis in the U.S. expected to worsen by 2050